Encoded Therapeutics Reels In $275 Million

<p><strong>SOUTH SAN FRANCISCO<&sol;strong> &&num;8212&semi; Encoded Therapeutics&comma; a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders&comma; has closed &dollar;275 million financing round&period; The financing was co-led by GV and another healthcare fund&comma; with participation from ARCH Venture Partners&comma; Braidwell LP&comma; Farallon Capital Management&comma; Illumina Ventures&comma; Invus&comma; Janus Henderson Investors&comma; Matrix Capital Management&comma; Nolan Capital&comma; RTW Investments&comma; SoftBank Vision Fund 2&comma; and Venrock&period;<&sol;p>&NewLine;<p>Proceeds will support the pivotal study of ETX101 in infants and young children with <i>SCN1A<&sol;i>&plus; Dravet syndrome&comma; as well as an expansion study in children and adolescents up to 18 years of age&period; Funding will also support commercial scale-up of internal GMP manufacturing capabilities and pipeline advancement&comma; including ETX301 toward a 2027 Investigational New Drug &lpar;IND&rpar; submission for post-amputation neuroma pain&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The interim Phase 1&sol;2 POLARIS data we recently shared at the European Epilepsy Congress demonstrate substantial and sustained seizure frequency reductions alongside encouraging developmental gains&period; This progress strengthens our conviction in ETX101 and the potential of our approach to meaningfully alter the course of Dravet syndrome&comma;” said Kartik Ramamoorthi&comma; Ph&period;D&period;&comma; Chief Executive Officer of Encoded&period; &OpenCurlyDoubleQuote;With pivotal development underway&comma; this financing gives us the resources to advance ETX101 toward registration while continuing to build the capabilities and pipeline that will define Encoded’s next stage&period;”<&sol;p>&NewLine;<p>&&num;8220&semi;The emerging clinical profile of ETX101 is increasingly compelling with durable seizure control and promising neurodevelopmental signals&comma; reinforcing its potential as a transformative therapy&comma;” said Brendan Bulik-Sullivan&comma; Ph&period;D&period;&comma; General Partner at GV&period; &OpenCurlyDoubleQuote;We are pleased to co-lead this financing and support Encoded as it advances ETX101 through pivotal development&period;&&num;8221&semi;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Progress with ETX101 provides important validation of Encoded’s differentiated approach to genetic medicine and the broader potential of its platform&comma;” added David Schenkein&comma; M&period;D&period;&comma; General Partner and Co-Lead of Life Sciences at GV&period; &OpenCurlyDoubleQuote;Encoded is well positioned to build a significant portfolio of medicines across neurological diseases&comma; where more precise and durable biological intervention could meaningfully improve outcomes&period;”<&sol;p>&NewLine;